Get the Stockscreener App
1.15
4.17%
-0.05
After Hours:
1.10
-0.05
-4.35%
Werewolf Therapeutics Inc stock is traded at $1.15, with a volume of 742.80K.
It is down -4.17% in the last 24 hours and down -40.41% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.20
Open:
$1.18
24h Volume:
742.80K
Relative Volume:
0.97
Market Cap:
$52.59M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.1058
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-12.21%
1M Performance:
-40.41%
6M Performance:
+24.86%
1Y Performance:
-48.66%
1-Day Range:
$1.07
$1.19
1-Week Range:
$1.07
$1.33
52-Week Range:
$0.595
$2.39
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.15 | 58.25M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
FY2025 Earnings Estimate for HOWL Issued By Leerink Partnrs - Defense World
Wedbush Expects Increased Earnings for Werewolf Therapeutics - Defense World
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for ... - Bluefield Daily Telegraph
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $295k By Investing.com - Investing.com South Africa
Werewolf Therapeutics: Multiple 10% owners sell $295k in shares By Investing.com - Investing.com Philippines
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $295k - Investing.com India
Werewolf Therapeutics: Multiple 10% owners sell $295k in shares - Investing.com India
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $189,830 - Investing.com India
Evnin Luke sells Werewolf Therapeutics (HOWL) stock for $189,830 By Investing.com - Investing.com Canada
[Form 4] Werewolf Therapeutics, Inc. Insider Trading Activity - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - MSN
How Werewolf Therapeutics Inc. stock performs after earningsJuly 2025 WrapUp & Verified Chart Pattern Signals - newser.com
Visual trend scoring systems applied to Werewolf Therapeutics Inc.July 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Werewolf Therapeutics Inc. stock trend forecastWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Is Werewolf Therapeutics Inc. stock bottoming out2025 Biggest Moves & Safe Swing Trade Setups - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
Will Werewolf Therapeutics Inc. price bounce be sustainableMarket Performance Recap & Community Consensus Stock Picks - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexes2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
How to read the order book for Werewolf Therapeutics Inc.Analyst Upgrade & Technical Pattern Based Signals - newser.com
Analyzing recovery setups for Werewolf Therapeutics Inc. investors2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Advanced analytics toolkit walkthrough for Werewolf Therapeutics Inc.Weekly Investment Report & AI Based Buy and Sell Signals - newser.com
Will Werewolf Therapeutics Inc. stock recover faster than market2025 Market Outlook & Risk Managed Investment Signals - newser.com
Wedbush Halves Price Target on Werewolf Therapeutics to $3 From $6, Keeps Outperform Rating - MarketScreener
Werewolf Therapeutics Narrows Losses And Wins FDA Fast Track Nod - Finimize
Why Werewolf Therapeutics Inc. stock is rated strong buyTake Profit & Safe Capital Growth Stock Tips - fcp.pa.gov.br
Identifying reversal signals in Werewolf Therapeutics Inc.July 2025 Momentum & Consistent Profit Alerts - newser.com
What MACD signals say about Werewolf Therapeutics Inc.2025 Price Action Summary & Low Risk Entry Point Tips - newser.com
Werewolf Therapeutics Reports Q3 2025 Financial Results - TipRanks
Luke Evnin Sells 55,795 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 60,369 Shares - MarketBeat
Bioventures 2014 L.P. Mpm Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 114,044 Shares of Stock - MarketBeat
Ansbert Gadicke Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 114,044 Shares - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 94,063 Shares of Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $121,341.27 in Stock - MarketBeat
Werewolf Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses - MarketScreener
[8-K] Werewolf Therapeutics, Inc. Reports Material Event | HOWL SEC FilingForm 8-K - Stock Titan
Werewolf Therapeutics (NASDAQ: HOWL) says cash funds operations into Q4 2026 - Stock Titan
Is Werewolf Therapeutics Inc. reversing from oversold territory2025 Top Decliners & Proven Capital Preservation Methods - newser.com
Werewolf therapeutics director Evnin sells $251k in HOWL stock - Investing.com India
Werewolf therapeutics director Evnin sells $251k in HOWL stock By Investing.com - Investing.com Australia
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):